Focalin XR(TM) Approved for Treatment of ADHD in Adults, Adolescents and Children
Posted on: Friday, 10 June 2005, 12:00 CDT
NEW YORK, June 10 /PRNewswire/ -- THIS IS A MULTIVU SPECIAL REPORT.
THE FDA HAS JUST APPROVED FOCALIN XR(TM), A NEW LONG-ACTING MEDICATION FOR ADULTS, ADOLESCENTS AND CHILDREN WHO STRUGGLE WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER ALSO KNOWN AS ADHD. IN ADULTS, ADOLESCENTS AND CHILDREN, THE CORE SYMPTOMS OF ADHD ARE INATTENTION, IMPULSIVITY AND HYPERACTIVITY. APPROXIMATELY 50 TO 70 PERCENT OF CHILDREN WITH ADHD WILL CONTINUE TO EXPERIENCE SYMPTOMS INTO ADULTHOOD.
DOCTOR LENARD ADLER, ASSOCIATE PROFESSOR OF CLINICAL PSYCHIATRY AND NEUROLOGY, NYU SCHOOL OF MEDICINE:
"Ideally when we're looking for effects of ADHD medication, we're looking for a medicine that will start quickly, have effects throughout the day and this is what Focalin XR has been shown to do. When an adult gets their ADHD treated, a variety of things may improve in their life: their work performance may improve, the quality of their relationships may improve, and their ability to get things done may also get better."
FOR MORE INFORMATION ABOUT ADHD TREATMENT WITH FOCALIN XR, VISIT http://www.focalinxr.com/. I'M ALICE LOOK.
NOTE TO PRODUCERS: Like most drugs approved for the treatment of ADHD, Focalin XR is contraindicated in patients known to be hypersensitive to the drug or to methylphenidate, in patients with glaucoma, and in patients with motor tics or with a family history or diagnosis of Tourette's syndrome. It is also contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result). In addition, like most drugs approved for the treatment of ADHD, Focalin XR is a schedule II drug and should be given cautiously to patients with a history of drug dependence or alcoholism.
ADDITIONAL RESOURCES: Audio version and more available at http://www.prnewswire.com/broadcast/21987/consumer.shtml
AUDIO PROVIDED BY: Novartis Pharmaceuticals
Audio: http://www.prnewswire.com/broadcast/21987/press.shtml
Novartis Pharmaceuticals
CONTACT: MultiVu, 1-800-653-5313, ext. 3 or email radio@multivu.com
Web site: http://www.multivu.com/http://www.focalinxr.com/
Source: PRNewswire
Related Articles
- FDA-Approved Drugs Eliminate, Prevent Cervical Cancer In Mice
- The Seventh Annual TV Land Awards to Honor 'M*A*S*H,' 'Married with Children,' 'Home Improvement,' 'Magnum P.I.,' 'Knots Landing' and 'Two and a Half Men' Among Others
- Women's Health Symposium to Focus on Patient Safety Through Technology and Improved Communication
- First Patient Enrolled in SONOMA Post-Market Approval Study of Boston Scientific NexStent(R) Carotid Stent System and FilterWire EZ(TM) Embolic Protection Device
- FDA Approves Drug for Type 2 Diabetes
- FDA Approves Drug for Autism Irritability
- For Patients, Inc.'s CathSling(TM) Has Been Approved for Medicare Reimbursement
- Many U.S. Post-Approval Drug Studies Unfinished
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
- Board to Track FDA-Approved Drugs' Safety
 |
 |
User Comments (0)
RSS Feeds